+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.

Age: 18Years +All GendersPhase 3
433 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are studying Alzheimers disease AD and mild cognitive impairment MCI to better understand molecular and genetic differences among patient subtypes and how these differences relate to disease progression. This observational study also includes cognitively normal participants as controls. The goal is to gather detailed molecular and clinical information that could inform future therapies and clinical strategies. Participants will provide samples such as olfactory neuron cells and blood at several visits over the study period. They will also complete cognitive and clinical assessments both in person and virtually. The study tracks changes over time, aiming to capture molecular signatures that distinguish different participant groups. During the study, participants will attend baseline and follow-up visits for up to 18 months. Assessments include cognitive tests like the Clinical Dementia Rating Sum of Boxes CDR-SB, Mini-Mental State Examination MMSE, and Rey Auditory Verbal Learning Test RAVLT. Researchers will analyze changes in molecular profiles from olfactory neurons and blood, monitor progression of cognitive symptoms, and collect detailed medical histories. Participants will be observed for safety and adherence throughout the study.

Age: 55Years +All Genders
1 location
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
S

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 combined with chemotherapy in people with advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma who have not received prior treatment for their advanced disease. This Phase 23 trial aims to evaluate the safety and effectiveness of PF-08634404 with chemotherapy compared to an approved treatment nivolumab plus chemotherapy for this type of cancer. Participants receive PF-08634404 or nivolumab intravenously along with chemotherapy in repeated treatment cycles. The study has two parts the first part focuses on assessing safety and response to the study medicine combined with chemotherapy, while the second part compares the study medicine plus chemotherapy to nivolumab plus chemotherapy to see which treatment works better. During the trial, participants undergo medical tests to monitor safety, treatment response, and cancer progression using established criteria. Researchers measure outcomes such as objective response rate, progression-free survival, overall survival, and quality of life over approximately four years. Adverse events, laboratory results, and drug concentrations are also tracked throughout treatment and for 90 days after the last intervention.

Age: 18Years +All GendersPhase 2Phase 3
102 locations
P

Actively Recruiting

Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.

Age: 18Years +All GendersPhase 3
484 locations